Autoimmune Hepatitis

Detailed Overview

AIH is broadly classified into two types based on autoantibody profiles: Type 1 (ANA or SMA positive) and Type 2 (anti-LKM1 or anti-LC1 positive). Type 1 is more common and affects adults, while Type 2 primarily presents in childhood and tends to be more severe. The clinical presentation ranges from asymptomatic transaminitis to acute liver failure. Prompt initiation of immunosuppressive therapy is critical to induce remission, prevent disease progression, and improve survival. Relapse is common upon medication withdrawal, necessitating long-term maintenance therapy in the majority of patients.

Epidemiology & Demographics

Prevalence is roughly 15-25 per 100,000 population in North America. Incidence is 1-2 per 100,000 annually. It has a strong female predominance with a 3-4:1 female-to-male ratio. Type 1 AIH has a bimodal age distribution peaking at ages 10-20 and 45-70.

Etiological Mechanism

The exact cause is unknown, but it is believed to result from an environmental trigger (e.g., viruses like HAV, EBV, or drugs like minocycline, nitrofurantoin) in a genetically susceptible individual (associated with HLA-DRB1*0301 and HLA-DRB1*0401 in European descents).

Primary Causes

Primary cause is an aberrant autoimmune response against hepatocytes. Secondary drug-induced AIH can occur with agents such as minocycline, nitrofurantoin, infliximab, and immune checkpoint inhibitors (e.g., pembrolizumab).

• Female Sex: Accounts for up to 80% of AIH cases.
• Genetic Predisposition: Presence of HLA-DR3 (associated with early onset and severe disease) or HLA-DR4 (associated with late onset and better response).
• Concurrent Autoimmune Diseases: History of autoimmune thyroiditis, celiac disease, or type 1 diabetes increases risk.
• Medication Exposure: Use of specific drugs like minocycline or nitrofurantoin which can trigger an AIH-like syndrome.

Loss of immunological tolerance to hepatocellular antigens results in a T-cell-mediated immune attack. CD4+ Th0 cells recognize autoantigens presented by HLA class II molecules on antigen-presenting cells. This leads to Th1/Th2 differentiation, cytokine secretion (IFN-gamma), and CD8+ cytotoxic T-cell activation which directly injure hepatocytes. Defective CD4+CD25+ regulatory T cells (Tregs) fail to suppress this response. B cells undergo activation and clonal expansion, producing autoantibodies and causing hypergammaglobulinemia.

Characteristic Clinical Presentation

• Fatigue: The most common and often debilitating symptom, reported by up to 85% of patients.
• Right Upper Quadrant Pain: Dull aching discomfort due to stretching of the liver capsule from inflammation.
• Jaundice: Yellowing of the skin and sclerae, indicating significant hepatic dysfunction or acute flare.
• Arthralgias: Joint pain, often affecting small joints symmetrically, due to systemic inflammation.

Physical Examination Signs

• Hepatomegaly
• Scleral Icterus
• Spider Angiomas
• Palmar Erythema

• Cirrhosis: Develops in 10-20% of cases despite therapy, leading to irreversible liver architectural distortion.
• Hepatocellular Carcinoma: Increased risk (1-2% annually) in patients who have progressed to cirrhosis.
• Hepatic Encephalopathy: Confusion and altered mental status resulting from acute liver failure or decompensated cirrhosis.
• Osteoporosis: Complication of long-term corticosteroid therapy used for disease management.

Diagnostic Criteria & Guidelines

Diagnosis is based on the revised original or simplified International Autoimmune Hepatitis Group (IAIHG) criteria. The simplified score includes: 1. Autoantibodies (ANA, SMA, LKM-1) with titers >= 1:40 (1 point) or >= 1:80 (2 points). 2. IgG > ULN (1 point) or > 1.1x ULN (2 points). 3. Liver histology showing interface hepatitis (1 point) or typical AIH (2 points). 4. Absence of viral hepatitis (2 points). A score >= 6 indicates probable AIH, and >= 7 indicates definite AIH.

Differential Diagnosis

• Viral Hepatitis (HBV, HCV)
• Primary Biliary Cholangitis (PBC)
• Primary Sclerosing Cholangitis (PSC)
• Drug-Induced Liver Injury (DILI)
• Wilson Disease

Laboratory Tests & Biomarkers

• AST and ALT: Typically elevated 2 to 10+ times the upper limit of normal.
• IgG Level: Elevated > 1.1 times the upper limit of normal (e.g., > 1600 mg/dL).
• Antinuclear Antibodies (ANA): Positive in 70-80% of Type 1 AIH (titer >= 1:40).
• Anti-Smooth Muscle Antibodies (ASMA): Positive in up to 70% of Type 1 AIH (often targeting F-actin).
• Anti-LKM1: Positive in Type 2 AIH, primarily targeting cytochrome P450 2D6.

Imaging Modalities & Findings

• Ultrasound:
• Elastography (FibroScan):

• Mild/Asymptomatic
  Incidentally discovered transaminitis, minimal or no fibrosis (F0-F1), AST/ALT < 3x upper limit of normal.
• Active Hepatitis
  Symptomatic with fatigue, marked elevation of AST/ALT (> 5-10x ULN), high IgG, interface hepatitis on biopsy.
• Cirrhosis
  Presence of bridging fibrosis or nodular regeneration (F4). Portal hypertension, varices, ascites, or encephalopathy.

Second-Line & Adjunctive Therapy

For patients refractory or intolerant to first-line therapy: Mycophenolate mofetil (MMF) 1000 mg twice daily orally. Tacrolimus 1-4 mg/day orally targeting trough levels of 3-5 ng/mL.

Surgical & Procedural Management

Liver transplantation is indicated for patients presenting with fulminant hepatic failure or decompensated cirrhosis (MELD score >= 15) who do not respond to medical therapy. Patient survival post-transplant is roughly 80-90% at 5 years.

Recommended Lifestyle Changes

• Strict alcohol abstinence to prevent additive hepatocellular injury.
• Adequate calcium (1000-1200 mg/day) and Vitamin D (800-1000 IU/day) supplementation to prevent steroid-induced bone loss.
• Weight-bearing exercises to maintain bone density and muscle mass.
• Vaccination against Hepatitis A and B, pneumococcus, and influenza.

Patient Counseling & Advice

Patients must be counseled on the high risk of disease relapse (up to 50-80%) if medications are discontinued, emphasizing the necessity of lifelong therapy for most. Inform about potential adverse effects of prolonged corticosteroid use, such as weight gain, osteoporosis, diabetes, and mood changes.

Follow-Up & Monitoring Schedule

Liver function tests (AST, ALT, Bilirubin) and IgG every 3-6 months. DEXA scan at baseline and every 1-2 years for patients on long-term steroids. If cirrhotic, HCC screening with ultrasound every 6 months and endoscopic screening for varices.

Preventive Strategies

No specific primary prevention exists as the exact trigger is unknown. Secondary prevention focuses on adherence to immunosuppressive regimens to prevent flares and progression to cirrhosis.

With adequate treatment, the 10-year survival rate exceeds 90% and is comparable to the general population. Poor prognostic indicators include young age at onset, presence of cirrhosis at diagnosis, and failure of transaminases to fall by 50% within 2 weeks of therapy.